Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
certolizumab pegol + cisplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- UCB
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Certolizumab pegol + cisplatin + pemetrexed is a combination therapy investigated by Memorial Sloan Kettering Cancer Center for the treatment of stage IV lung adenocarcinoma. Certolizumab pegol is a PEGylated, humanized antigen-binding fragment (Fab') of a TNF-alpha monoclonal antibody that neutralizes the pro-inflammatory cytokine TNF-alpha. Cisplatin is a platinum-based chemotherapy agent that cross-links DNA, while pemetrexed is a folate antimetabolite that inhibits multiple enzymes involved in pyrimidine and purine synthesis. The therapeutic rationale for this combination is based on the observation that chemotherapy can induce a TNF-alpha-mediated inflammatory loop that promotes tumor survival and metastasis; by adding certolizumab pegol, researchers aim to disrupt this loop and enhance the efficacy of the standard-of-care cisplatin/pemetrexed regimen in advanced lung cancer patients.
- Brand names
- CimziaAlimtaPlatinol
- Other names
- CertolizumabCZP
02
Targets
TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)GART (GAR transformylase)TNFA (Tumor necrosis factor alpha (soluble))DNA
Beyond the preview
Go deeper on certolizumab pegol + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on certolizumab pegol + cisplatin + pemetrexed.